



**Living Cell Technologies Limited**  
**Company Announcement**

**LCT granted USA Patent for Auckland Island Pigs**

**1 February 2012** – Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that it has been granted U.S. Patent No. 8,088,969 from the United States Patent and Trademark Office (USPTO). The patent, which was issued on 3 January 2012 and expires on 10 November 2028, provides exclusive rights to the use of cells and tissue derived from Auckland Island pigs for xenotransplantation therapies. It protects the holder's ability to commercialise therapies based on its core cell encapsulation and xenotransplantation capabilities.

The original Auckland Island pig herd has been developed by LCT over the last decade to produce a unique stock of pigs which are free from disease and, in particular, do not transmit pig viruses to human cells. The pigs are housed in bio-isolation facilities in New Zealand, and cells are harvested for the treatment of human diseases. Regulatory authorities in New Zealand, Argentina and Russia have judged the cells free of infectious organisms and safe for human recipients.

Professor Bob Elliott, LCT's Medical Director said, "A disease-free source herd is an absolute requirement for transplantation of animal cells into humans. The discovery of the Auckland Island herd, its subsequent development and the characterisation of its disease-free properties is the foundation of LCT's human xenotransplantation trials for diabetes and degenerative neurological conditions."

The patent will be assigned to Diatranz Otsuka Limited (DOL), a joint venture company established by LCT and Otsuka Pharmaceutical Factory, Inc. to commercialise xenotransplantation for the treatment of Type 1 diabetes. LCT has a 50 per cent shareholding in DOL, and a service agreement to supply research and development and administrative services to the joint venture. Under the JV agreement DOL will ensure ongoing supply of pig cells to LCT for use in developing new xenotransplantation treatments in non-diabetes related disease areas, including neurodegenerative disorders.

Dr Andrea Grant, LCT's CEO, said, "This patent is a key milestone in the commercialisation of DIABECCELL® as it grants exclusive rights to use the Auckland Island pigs for xenotransplantation in the USA. Under our supply agreement with DOL, the patent also protects any future exclusively owned products LCT may develop including NTCELL, which LCT is developing for the treatment of neurodegenerative disorders, in particular Parkinson's disease."

- Ends -

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

**At the company:**

Andrea Grant, Chief Executive  
Tel: +64 9 276 2690

**Media and investor enquiries:**

Andrea Grant, Chief Executive  
Tel: +64 9 276 2690

Mobile: +64 21 0785 421 <a href="mailto:agrant@lctglobal.com">agrant@lctglobal.com</a>	Mobile: +64 21 0785 421 <a href="mailto:agrant@lctglobal.com">agrant@lctglobal.com</a>
---	---

## **About Living Cell Technologies - [www.lctglobal.com](http://www.lctglobal.com)**

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. The Company's lead product, DIABECCELL<sup>®</sup>, consists of microencapsulated porcine islets which are implanted into a patient's abdomen using a simple laparoscopic procedure. DIABECCELL is designed to help normalise the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. The Company entered clinical trials for its diabetes product in 2007 and very encouraging results have been reported to date. There have been no reports of remarkable product related adverse events. For the treatment of Parkinson's disease and other neurological disorders, the company implants microencapsulated choroid plexus cells NTCELL that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

### ***LCT Disclaimer***

*This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.*

---

+ See chapter 19 for defined terms.